Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 705-716

  Dawson, Nancy A ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Bisphosphonates; Bone metastases; Osteoporosis; Prostate cancer

Indexed keywords

ALENDRONIC ACID; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; ESTROGEN; ETIDRONIC ACID; GONADORELIN AGONIST; IBANDRONIC ACID; OLPANDRONIC ACID; PAMIDRONIC ACID; PHOSPHONIC ACID DERIVATIVE; PLACEBO; RISEDRONIC ACID; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ANEMIA; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BONE PAIN; BREAST TENDERNESS; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FEVER; GYNECOMASTIA; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; INCIDENCE; KIDNEY FAILURE; LEG EDEMA; MEDICAL DECISION MAKING; MYALGIA; NONHUMAN; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; PATHOLOGIC FRACTURE; PATIENT SELECTION; PHYSICIAN; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; SECONDARY OSTEOPOROSIS; STRUCTURE ANALYSIS; THROMBOEMBOLISM;

ANDROGENS; BONE NEOPLASMS; DIPHOSPHONATES; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0038811682     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.705     Document Type: Review

References (104)

1. JEMAL A, THOMAS A, MURRAY T, THUN M: Cancer statistics 2002, CA, USA. Cancer J. Clin. (2002) 52:23-47.
2. PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: GLOBOCAN 2000. Int. J. Cancer (2001) 94:153-156.
3. POUND CR, PARTIN AW, EISENBERGER MA, CHAN DW, PEARSON JD, WALSH PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 281:1591-1597.
4. JACOBS SC: Spread of prostate cancer to bone. Urology (1983) 21:337.
5. CARLIN BI, ANDRIOLE G: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer (2000) 88(Suppl. 12):S2989-S2994.
6. PATAKI A, MULLER K, GREEN JR, MA YF, LI QN, JEE WSS: Effects of short-term treatment with die bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during and after treatment. Anat. Rec. (1997) 249: 458-468.
7. ROODMAN GD: Biology of osteoclast activation in cancer. J. Clin. Oncol. (2001) 19:3562-3571.
8. LIPTON A, COSTAL, ALI S, DEMERS L: Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin. Oncol. (2001) 28:54-59.
9. SAHARABUDHE C, MAURER C, HASSETT R et al.: Effect of androgen-ablation on bone resorption in men with prostate cancer. Proc. Amer. Soc. Clin. Oncol. (2001) 20:184a (Abstract 734).
10. GARNERO P, BUCHS N, ZEKRI J et al.: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer (2000) 4:858-864.
11. GREEN JR, ROGERS MJ: Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev. Res. (2002) 55:210-224.
12. BERRUTI A, DOGLIOTTI L, TUCCI M et al.: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J. Urol. (2001) 166:2023-2031.
13. DUNFORD JE, THOMPSON K, COXON FP et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharm. Exp. Ther. (2001) 296:235-242.
14. VIRTANEN SS, VAANANEN HK, HARKONEN PL, LAKKAKORPI PT: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. (2002) 62:2708-2714.
15. KREMPIEN B, WIPFLER G, MANEGOLD CH et al.: Prevention and therapy of minor induced osteolysis by pharmacological antiolysis. J. Cancer Res. Clin. Oncol. (1992) 118(Suppl.):R81 (Abstract V4.10.04).
16. SAAD F, GLEASON DM, MURRAY R et al.: A randomized, placebo-controlled trial of zoledronic add in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. (2002) 94:1458-1468.
17. BODY J-J: Dosing regimens and main adverse events of bisphosphonates. Sem. Oncol. (2001) 28(Suppl. 2):49-53.
18. LOOKER AC, ORWOLL ES, JOHNSTON CC Jr et al.: Prevalence of low femoral bone density in older US adults from NHANES III. Bone Miner. Res. (1997) 12:1761-1768.
19. COOPER C, CAMPION G, MELTON LJ et al.: Hip fractures in the elderly: a worldwide projection. Osteopor. Int. (1992) 2:285-289.
20. POOR G, ATKINSON EJ, O'FALLON WM, MELTON LJ 3rd: Determinants of reduced survival following hip fractures in men. Clin. Orthop. Relat. Research (1995) 319:260-265.
21. BAILLIE SP, DAVISON CE, JOHNSON FJ, FRANCIS RM: Pathogenesis of vertebral crush fractures in men. Age and Ageing (1992) 21:139-141.
22. BILEZIKIAN JP: Osteoporosis in men. J. Clin. Endocrinol. Metab. (1999) 84:3431-3434.
23. JACKSON JA, KLEEREKOPER M, PARFITT AM, RAO DS, VILLANUEVA AR, FRAME B: Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J. Clin. Endocrinol. Metab. (1987) 65:53-58.
24. STEPAN JJ, LACHMAN M, ZVERINA J, PACOVSKY V, BAYLINK DJ: Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J. Clin. Endocrinol. Metab. (1989) 69:523-527.
25. COLLINSON MP, TYRRELL CJ, HUTTON C et al.: Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif. Tissue Int. (1994) 54:327-328.
26. MCGRATH SA, DIAMOND T: Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J. Urol. (1995) 154:535-536.
27. ROSS RW, SMALL EJ: Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J. Urol. (2002) 167:1952-1956.
28. SMITH MR: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology (2002) 60:79-85.
29. WEI JT, GROSS M, JAFFE CA et al.: Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology (1999) 54:607-611.
30. KIRATLI BJ, SRINIVAS S, PERKASH I, TERRIS MK: Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology (2001) 57:127-132.
31. HIGANO CS, STEPHENS C, NELSON P et al.: Prospective serial measurements of bone mineral density (BMD) in prostate cancer patients without bone metastases treated with intermittent androgen suppression (IAS). Proc. Amer. Soc. Clin. Oncol. (1999) 18:314a (Abstract 1207).
32. DANIELL HW: Osteoporosis after orchiectomy for prostate cancer. J. Urol. (1997) 157:439-444.
33. TOWNSEND MF, SANDERS WH, NORTHWAY RO, GRAHAM JR SD: Bone fractures associated with leuteinizig hormone-releasing hormone agonists used in treatment of prostate carcinoma. Cancer (1997) 79:545-550.
34. OEFELEIN MG, RICCHUITI V, CONRAD W et al.: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J. Urol. (2001) 166:1724-1728.
35. DIAMOND T, CAMPBELL J, BRYANT C, LYNCH W: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer (1998) 83:1561-1266.
36. DIAMOND TH, WINTERS J, SMITH A et al.: The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade, a double blind, randomized, placebo-controlled crossover study. Cancer (2001) 92:1444-1450.
37. ORWOLL E, ETTINGER M, WEISS S et al.: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. (2000) 343:604-610.
38. REID IR, BROWN JP, BURCKHARDT P et al.: Intravenous zoledronic acid in postmenopausal women with low mineral density. N. Engl. J. Med. (2002) 346:653-661.
39. MUKHERJEE T, BARAD D, TURK R, FREEMAN R: A randomized placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. Am. J. Ostet. Gynecol. (1996) 175:105-109.
40. CLARKE NW, MCCLURE J, GEORGE NJ et al.: The effects of orchiectomy on skeletal metabolism in metastatic prostate cancer. Scand. J. Urol. Nephrol. (1993) 27:475-483.
41. SMITH MR, MCGOVERN FJ, ZIETMAN AL et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. (2001) 345:948-95.
42. SMITH MR, SHASHA D, MANSOUR R et al.: Zometa increases bone mineral density in men undergoing androgen deprivation therapy for prostate cancer. Skeletal Complications of Malignancies. 3rd North American Symposium, Meeting Proceeding, Bethesda, MD, USA (2002) C8:25-27 (Abstract).
43. DANIELL HW, DUNN S, FERGUSON D, LOMAS G, NIAZI Z, STRATTE PT: Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J. Urol. (2000) 163:181-186.
44. MOYAD MA: Complementary therapies for reducing the risk of osteoporosis in patients receiving leuteinizig hormone-releasing hormone treatment/orchiecotmy for prostate cancer: a review and assessment of the need for more research. Urology (2002) 59:34-40.
45. BILEZIKIAN JP, PANEL MEMBERS: Optimal calcium intake-statement of the consensus development panel on optimal calcium intake. JAMA (1994) 272:1942-1948.
46. Dietary references intakes: Food and Nutrition Board, Institute of Medicine, National Research Council, Washington, DC, USA. National Academy Press (1998).
47. DAWSON-HUGHES B, HARRIS SS, KRALL EA, DALLAL GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age and older. N. Engl. J. Med. (1997) 337:670-676.
48. SUZUKI Y, OISHI Y, YAMAZAKI H et al.: How to avoid bone loss in patients with prostatic carcinoma receiving long-term LHRH-analogue. J. Urol. (2000) 163:159 (Abstrac 707).
49. ERIKSSON S, ERIKSSON A, STEGE R, CARLSTROM K: Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif. Tissue Int. (1995) 57:97-99.
50. CARLSTROM K, STEGE R, HENRIKSSON P, GRANDE M, GUNNARSSON PO, POUSETTE A: Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate (1997) 31:193-197.
51. IVERSON P, TYRRELL CJ, KAISARY AV et al.: Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years of follow-up. J. Urol. (2000) 164:1579-1582.
52. BOCCARDO F, BARICHELLO M, BATTAGLIA M et al.: Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. Eur. Urol. (2002) 42:481-490.
53. ABRAHAMSSON PA: Treatment of locally advanced prostate cancer a new role for antiandrogen monotherapy? Eur. Urol. (2001) 39:22-28.
54. IGLESIAS CP, TORGERSON DJ, BEARNE A, BOSE U: The cost utility of bisphosphonate treatment in established osteoporosis. QJM (2002) 95:305-311.
55. CHRISCHILLES EA, DASBACH EJ, RUBENSTEIN LM, COOK JR, TABOUR HK, BLACK DM: The effect of aledronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Fracture Intervention Trial Research Group. Osteoporos. Int. (2001) 12:654-660.
56. DESHARNAIS CASTEL L, BAJWA K, MARKLE JP, TIMBIE JW, ZACKER C, SCHULMAN KA: A microcosting analysis of zoledronic acid and pamidronate therapy with metastatic bone disease. Support. Care Cancer (2001) 9:545-551.
57. BERRUTI A, DOGLIOTTI L, BITOSSI R et al.: Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. (2000) 164:1248-1253.
58. ROBSON M, DAWSON N: How is androgen dependent metastatic prostate cancer best treated? Hematol. Oncol. Clin. N. Am. (1996) 10:727-747.
59. OFELEIN MG, RICCHIUTI V, CORAD W, RESNICK MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. (2002) 168:1005-1007.
60. CHEN TC: Prostate cancer and spinal cord compression. Oncology (Huntingt.) (2001) 15:841-855.
61. SMITH JA, SOLOWAY MS, YOUNG MJ et al.: Complications of advanced prostate cancer. Urology (1999) 54:8-14.
62. DEMERS LM, COSTA L, LIPTON A et al.: Biochemical markers and skeletal metastases. Cancer (2000) 88:2919-2926.
63. GARNERO P: Markers of bone turnover in prostate cancer. Cancer Treat. Rev. (2001) 3:187-192.
64. HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl. J. Med. (1996) 335:1785-1791.
65. THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lyric bone lesions: a randomized placebo-controlled trial. J. Clin. Oncol. (1999) 17:846-854.
66. LIPTON A, THERIAULT RL, HORTOBAGYI GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Cancer (2000) 88:1082-1090.
67. ROSEN LS, GORDON D, KAMINISKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7:377-387.
68. BERENSON JR, LIECHTENSTEIN A, PORTER L et al.: Efficacy of pamidronate in reducing skeletal event in-patients with advanced multiple myeloma. N Engl. J. Med. (1996) 334: 488-493.
69. BERENSON JF, LICHTENSTEIN A, PORTER L et al.: Long- term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J. Clin. Oncol. (1998) 16:593-602.
70. BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clinical Oncology Practice Guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20:3719-3736.
71. HILLNER BE, INGLE JN, BERENSON JR et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J. Clin. Oncol. (2000) 18:1378-1391.
72. LIPTON A, SMALL E, SAAD F et al.: The new bisphosphonate, Zometa® (zoledronic acid) decreases skeletal complications in both lyric and blastic lesions: a comparison to pamidronate. Cancer Invest. (2002) 20(Suppl. 1):44-46.
73. MCCLOSKEY EV, GUEST JF, KANIS JA et al.: The clinical and cost considerations of bisphophonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs (2001) 61:1253-1274.
74. BRUCE NJ, MCCLOSKEY EV, KANIS JA, GUEST JF: Economic impact of using clodronate in the management of patients with multiple myeloma. Br. J. Hematol. (1999) 104:358-364.
75. BIERMANN WA, CANTOR RI, FELLIN FM, JAKOBOWSKI J, HOPKINS L, NEWBOLD RC 3rd: An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone (1991) 12:S37-S42.
76. BEUSTERIEN KM, HILL MC, ACKERMAN SJ, ZACKER C: The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. Support. Care Cancer (2001) 9:169-176.
77. DRANITSARIS G, HSU T: Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support. Care Cancer (1999) 7:271-279.
78. DRANITSARIS G: Pamidronate for the prevention of skeletal-related events in multiple myeloma: what does the public think it is worth? Int. J. Technol. Assess. Health Care (1999) 15:108-122.
79. ADAMI S, SALVANGNO G, GUARRERA G et al.: Dichloromethylenediphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol. (1985) 134:1152-1154.
80. ADAMI S, MIAN M: Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Cancer Res. (1989) 116:67-72.
81. ADAMI S: Bisphosphonates in prostate carcinoma. Cancer (1997) 80(Suppl. 8):1674-1679.
82. HEIDEREICH A, HOFMANN R, ENGELMANN UH et al.: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. (2001) 165:136-140.
83. STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anti-Cancer Res. (1997) 17:4717-4721.
84. KYLMALA T, TAUBE T, TAMMELA TL et al.: Concomitant i.v. and oral clodronate in the relief of bone pain-a double-blind, placebo controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76:939-942.
85. COLEMAN RE, PUROHIT OP, VINHOLES JJ et al.: High-dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer (1997) 80(Suppl. 8):1652-1660.
86. LIPTON A, GLOVER D, HARVEY H et al.: Pamidronate in the treatment of bone metastases: results of two dose-ranging trials in patients with breast or prostate cancer. Ann. Oncol. (1994) 5(Suppl. 7):S31-S35.
87. JOHNSON IS: Use of bisphosphonates for the treatment of metastatic bone pain - a survey of palliative physicians in the UK. Palliat. Med. (2001) 2:141-147.
88. PELGER RCM, HAMDY NAT, ZWIDERMAN AH et al.: Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone (1998) 22:403-408.
89. SOERDJBALIE-MAIKOE V, PELGER RCN, LYCKLAMA A NIJEHOLT AAB et al.: Palliation of bone pain by the bisphosphonate olpadronate in hormone-escaped prostate adenocarcinoma metastatic to the skeleton. J. Urol. (2000) 163:261.
90. HEIDENREICH A, VON KNOBLOCH R, ELERT A, HOFMANN R: Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis. (2002) 5:1-5.
91. LEE MV, FONG EM, SINGER FR, GUENETTE RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. (2001) 61:2602-2608.
92. CLEZARDIN P. GLIGOROV J, DELMAS P et al.: Mechanisms of action of bisphosphonates on tumor cells and prospects for use in treatment of malignant osteolysis. Joint Bone Spine (2000) 67:22-29.
93. BOISSIER S, MAGNETTO S, FRAPPART L et al.: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. (1997) 57:3890-3894.
94. BOSSIER S, FERRERAS M, PEYRUCHAUD O et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. (2000) 60:2949-2954.
95. TERONEN O, HEIKKILA P, KONTTINEN YT et al.: MMP inhibition and down regulation by bisphosphonates. Ann. NY Acad Sci. (1999) 878:453-465.
96. SUN Y, GELDOFF AA, NEWLING DW. RAO BR: Progression delay of prostate tumor skeletal metastatic effect by bisphosphonates. J. Urol. (1992) 148:1270-1273.
97. COLEMAN RE, SEAMAN JJ: The role of zoledronic acid in cancer clinical studies in the treatment and prevention of bone metastases. Semin. Oncol. (2001) 28(Suppl. 6):11-16.
98. DIEL IJ: Bisphosphonates in the prevention of bone metastases: current evidence Semin. Oncol. (2001) 28(Suppl. 6):75-80.
99. KANIS JA, POWLES TJ, PATERSON AHG et al.: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone (1996) 19:663-667.
100. DIEL IJ, SOLOMAYER EF, COSTA SD et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. (1998) 339:357-363.
101. DIEL IJ, SOLOMAYER EF, BASTERT G et al.: Bisphosphonates in the prevention of metastases in breast cancer results of the extended follow-up study. Proc. Am. Soc. Clin. Oncol. (2000) 19:314 (Abstract).
102. SAARTO T, BLOMQVIST C, VIRKKUNEN P, ELOMAA I: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer: 5-year results of a randomized controlled trial. J. Clin. Oncol. (2001) 19:10-17.
103. DEARNALEY DP, SYDES MR: Preliminary evidences that oral clodronate-delays symptomatic progression of bone metastases from prostate cancer: first results of the MRC PRO5 trial. the MRC PRO5 collaboration. Proc. Amer. Soc. Clin. Oncol. (2001) 20:174a (Abstract 693).
104. JONES J: Bisphosphonates may be useful in treatment of bone metastases. J. Natl. Cancer Inst. (2001) 93:1052-1053.